We aimed at molecularly dissecting the anatomical heterogeneity of small lymphocytic lymphoma (SLL), by analysing a cohort of 12 patients for whom paired DNA from a lymph node biopsy and circulating cells, as well as plasma-circulating tumour DNA (ctDNA) was available. Notably, the analyses of the lymph node biopsy and of circulating cells complement each other since a fraction of mutations (20·4% and 36·4%, respectively) are unique to each compartment. Plasma ctDNA identified two additional unique mutations. Consistently, the different synchronous sources of tumour DNA complement each other in informing on driver gene mutations in SLL harbouring potential prognostic and/or predictive value
Accessible and real-time genotyping for diagnostic, prognostic or treatment purposes is increasingly...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Sarcoma is a heterogeneous group of cancer of mesenchymal origin, with about 80 % of diagnosed cases...
Circulating tumour DNA (ctDNA) can be used to profile, detect, and monitor cancers. Technical advanc...
Diffuse large B-cell lymphoma is a molecular heterogeneous disease with a variable clinical course a...
Diffuse large B cell lymphomas (DLBCL) are the most common neoplasia of the lymphatic system. Circul...
The assessment of the cancer mutational profile is crucial for patient management, stratification, a...
Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identificat...
Liquid biopsy consists in a simple blood sampling that allows to analyze cell free DNA (cfDNA), cont...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identificat...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingl...
Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingl...
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia...
Accessible and real-time genotyping for diagnostic, prognostic or treatment purposes is increasingly...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Sarcoma is a heterogeneous group of cancer of mesenchymal origin, with about 80 % of diagnosed cases...
Circulating tumour DNA (ctDNA) can be used to profile, detect, and monitor cancers. Technical advanc...
Diffuse large B-cell lymphoma is a molecular heterogeneous disease with a variable clinical course a...
Diffuse large B cell lymphomas (DLBCL) are the most common neoplasia of the lymphatic system. Circul...
The assessment of the cancer mutational profile is crucial for patient management, stratification, a...
Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identificat...
Liquid biopsy consists in a simple blood sampling that allows to analyze cell free DNA (cfDNA), cont...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identificat...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingl...
Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingl...
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia...
Accessible and real-time genotyping for diagnostic, prognostic or treatment purposes is increasingly...
International audienceFrom a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding ...
Sarcoma is a heterogeneous group of cancer of mesenchymal origin, with about 80 % of diagnosed cases...